IR@PKUHSC  > 北京大学临床肿瘤学院  > 淋巴肿瘤内科
学科主题临床医学
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group
Kim, Seok Jin1; Hsu, Chiun2; Song, Yu-Qin3; Tay, Kevin4; Hong, Xiao-Nan5; Cao, Junning5; Kim, Jin Seok6; Eom, Hyeon Seok7; Lee, Joon Hyeok8; Zhu, Jun9; Chang, Kian-Meng10; Reksodiputro, Arry Harryanto11; Tan, Daryl12; Goh, Yeow Tee12; Lee, Jejung13; Intragumtornchai, Tanin14; Chng, Wee-Joo15; Cheng, Ann-Lii2; Lim, Soon Thye4; Suh, Cheolwon16; Kwong, Yok-Lam17; Kim, Won Seog1
关键词Hepatitis B virus Rituximab B-cell Lymphoma
刊名EUROPEAN JOURNAL OF CANCER
2013-11-01
DOI10.1016/j.ejca.2013.07.006
49期:16页:3486-3496
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者Roche Pharmaceutical ; Roche Pharmaceutical
研究领域[WOS]Oncology
关键词[WOS]HBSAG-NEGATIVE PATIENTS ; CYTOTOXIC CHEMOTHERAPY ; HBV REACTIVATION ; CANCER-PATIENTS ; RISK-FACTORS ; SYSTEMIC CHEMOTHERAPY ; PREEMPTIVE LAMIVUDINE ; MALIGNANT-LYMPHOMA ; PROSPECTIVE COHORT ; THERAPY
英文摘要

Background: Hepatitis B virus (HBV) reactivation is increasing, as rituximab has become widely used for B-cell lymphoma. Thus, prevention and management of HBV reactivation are important in HBV-endemic areas.

Methods: Hepatitis B virus (HBV) reactivation in HBV surface antigen (HBsAg)-positive patients and HBsAg-negative/HBV core antibody (HBcAb)-positive patients who received rituximab-containing chemotherapy was investigated by the Asia Lymphoma Study Group via retrospective (n = 340), and the results were compared to cross-sectional analysis with patients who were prospectively monitored in a single institute (n = 127). The goal of the study was to define the frequency of HBV reactivation and the efficacy of antiviral prophylaxis.

Results: HBV reactivation was found in 27.8% of HBsAg-positive patients (45/162) in the retrospective analysis, being significantly less frequent in patients receiving antiviral prophylaxis than those not (22.9%, 32/140 versus 59.1%, 13/22; p < 0.001). Lamivudine was most commonly used (96/162, 59.3%), but more than 20% of HBsAg-positive patients showed breakthrough HBV reactivation. In the cross-sectional analysis, a reduced rate of HBV reactivation occurred for entecavir as compared with lamivudine prophylaxis (6.3% versus 39.3%; p < 0.05). HBV DNA monitoring of HBsAg-negative/HBcAb-positive patients in the cross-sectional analysis showed HBV reactivation in only 2.4% of cases.

Conclusions: This is the largest study of HBV reactivation in patients receiving rituximab-containing chemotherapy to date, and we defined the probability of HBV reactivation in an HBV-endemic region. (C) 2013 Elsevier Ltd. All rights reserved.

语种英语
资助者Roche Pharmaceutical ; Roche Pharmaceutical
WOS记录号WOS:000325425800012
引用统计
被引频次:45[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61712
专题北京大学临床肿瘤学院_淋巴肿瘤内科
作者单位1.Ampang Hosp, Dept Hematol, Selangor, Malaysia
2.Singapore Gen Hosp, Dept Haematol, Singapore, Singapore
3.Asan Med Ctr, Dept Oncol, Seoul, South Korea
4.Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul 135710, South Korea
5.Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
6.Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Beijing 100871, Peoples R China
7.Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore
8.Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
9.Yonsei Univ, Coll Med, Dept Internal Med, Div Hematol, Seoul, South Korea
10.Natl Canc Ctr, Hematol Malignancy Branch, Gyeonggi Do, South Korea
11.Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Gastroenterol,Dept Med, Seoul, South Korea
12.Peking Univ, Dept Med, Canc Hosp, Beijing 100871, Peoples R China
13.Cipto Mangunkusumo Gen Hosp, Dept Internal Med, Div Hematol Oncol, Jakarta, Indonesia
14.Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Jeollanam Do, South Korea
15.Chulalongkorn Univ, Dept Med, Div Hematol, Bangkok, Thailand
16.Natl Univ Hlth Syst, Natl Univ Canc Inst Singapore, Dept Hematol Oncol, Singapore, Singapore
17.Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
推荐引用方式
GB/T 7714
Kim, Seok Jin,Hsu, Chiun,Song, Yu-Qin,et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group[J]. EUROPEAN JOURNAL OF CANCER,2013,49(16):3486-3496.
APA Kim, Seok Jin.,Hsu, Chiun.,Song, Yu-Qin.,Tay, Kevin.,Hong, Xiao-Nan.,...&Kim, Won Seog.(2013).Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group.EUROPEAN JOURNAL OF CANCER,49(16),3486-3496.
MLA Kim, Seok Jin,et al."Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group".EUROPEAN JOURNAL OF CANCER 49.16(2013):3486-3496.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Kim, Seok Jin]的文章
[Hsu, Chiun]的文章
[Song, Yu-Qin]的文章
百度学术
百度学术中相似的文章
[Kim, Seok Jin]的文章
[Hsu, Chiun]的文章
[Song, Yu-Qin]的文章
必应学术
必应学术中相似的文章
[Kim, Seok Jin]的文章
[Hsu, Chiun]的文章
[Song, Yu-Qin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。